Since last year, EFCNI has been involved as a third party representing the voice of patients and parents in the new conect4children (c4c) consortium, a research collaboration to build a European paediatric clinical trial network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population.

c4c now announced that it selected its first portfolio of pan-European paediatric studies aimed at advancing the understanding of high priority medicines commonly used in babies, children, and young people in Europe. The four inaugural studies will be conducted by academic institutions, in addition to three or four studies by industry partners, covering different diseases and age groups.

EFCNI is delighted to be an official partner of one of these four studies: “Paracetamol in Premature Babies” that will assess the effectiveness of paracetamol in preterm babies with a patent ductus arteriosus, and will recruit around 600 babies as part of the study. The study called TREOCAPA is led by Professor Jean-Christophe Roze of INSERM, a public research organisation in Paris, France entirely dedicated to human health. EFCNI will be heading the tasks “Dissemination and patient and public participation”.

We very much look forward to supporting this neonatology study representing the voice of parents and patients. We will publish regular updates in the coming months.

For further information, please have a look at www.conect4children.org, www.imi.europa.eu and the press release: https://bit.ly/2IMZiVB

Please note: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.